-
公开(公告)号:US20200055936A1
公开(公告)日:2020-02-20
申请号:US16493712
申请日:2018-03-13
Inventor: Robert J. Johnston , Arvind Rajpal , Paul O. Sheppard , Luis Borges , Andrew Rankin , Keith Sadoon Bahjat , Alan J. Korman , Andy X. Deng , Lin Hui Su , Ginger Rakestraw
IPC: C07K16/28
Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.
-
公开(公告)号:US10189902B2
公开(公告)日:2019-01-29
申请号:US14977789
申请日:2015-12-22
Applicant: Bristol-Myers Squibb Company
Inventor: Mark F. Maurer , Tseng-hui Timothy Chen , Brigitte Devaux , Mohan Srinivasan , Susan H. Julien , Paul O. Sheppard , Daniel F. Ardourel , Indrani Chakraborty
Abstract: The present invention provides antibodies, or antigen binding fragments thereof, that bind to human TIGIT (T cell immunoreceptor with Ig and ITIM domains), as well as uses of these antibodies or fragments in therapeutic applications, such as in the treatment of cancer or chronic viral infection. Such method of treatment include combination therapy with inhibitors of other immunomodulatory receptor interactions, such as the PD-1/PD-L1 interaction. The invention further provides polynucleotides encoding the heavy and/or light chain variable region of the antibodies, expression vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies, cells comprising the vectors, and methods of making the antibodies or fragments by expressing them from the cells.
-
公开(公告)号:US10023634B2
公开(公告)日:2018-07-17
申请号:US15649380
申请日:2017-07-13
Applicant: Bristol-Myers Squibb Company
Inventor: Xiao Min Schebye , Mark J. Selby , Michelle Minhua Han , Christine Bee , Andy X. Deng , Anan Chuntharapai , Brigitte Devaux , Huiming Li , Paul O. Sheppard , Alan J. Korman , Daniel F. Ardourel , Ekaterina Deyanova , Richard Huang , Guodong Chen , Michelle Kuhne , Hong-An Troung
Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.
-
公开(公告)号:US20130089517A1
公开(公告)日:2013-04-11
申请号:US13687851
申请日:2012-11-28
Applicant: Bristol-Myers Squibb Company
Inventor: Lowell J. Brady , Kevin M. Klucher , Chung Chan , Dennis L. Dong , Hong Y. Liu , Paul O. Sheppard , Thomas R. Bukowski
IPC: C07K14/54
CPC classification number: A61K38/20 , A61K38/00 , C07K14/54 , C07K14/555 , C07K2319/00 , Y10S435/81 , Y10S435/975 , Y10S514/894
Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.
Abstract translation: 已经通过在编码成熟蛋白的多核苷酸序列中突变一个或多个半胱氨酸残基来产生IL-28A,IL-28B和IL-29的均质制剂。 可以显示半胱氨酸突变蛋白与其同源受体结合或表现出生物活性。 所示的一种生物活性是抗病毒活性。
-
公开(公告)号:US12091462B2
公开(公告)日:2024-09-17
申请号:US17258866
申请日:2019-07-10
Inventor: Robert J. Johnston , Arvind Rajpal , Paul O. Sheppard , Luis Borges , Andrew Rankin , Keith Sadoon Bahjat , Alan J. Korman , Xiaodi Deng , Lin Hui Su , Ginger Rakestraw , Jason R. Pinckney , David A. Critton , Guodong Chen , Richard Y. Huang , Ekaterina G. Deyanova , Michael Quigley , Hadia Lemar , Akbar Nayeem
CPC classification number: C07K16/2827 , A61P35/00 , A61K2039/507 , C07K2317/34 , C07K2317/74 , C07K2317/76 , C07K2317/92
Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.
-
公开(公告)号:US11008390B2
公开(公告)日:2021-05-18
申请号:US16228095
申请日:2018-12-20
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: Mark F. Maurer , Tseng-hui Timothy Chen , Brigitte Devaux , Mohan Srinivasan , Susan H. Julien , Paul O. Sheppard , Daniel F. Ardourel , Indrani Chakraborty
Abstract: The present invention provides antibodies, or antigen binding fragments thereof, that bind to human TIGIT (T cell immunoreceptor with Ig and ITIM domains), as well as uses of these antibodies or fragments in therapeutic applications, such as in the treatment of cancer or chronic viral infection. Such method of treatment include combination therapy with inhibitors of other immunomodulatory receptor interactions, such as the PD-1/PD-L1 interaction. The invention further provides polynucleotides encoding the heavy and/or light chain variable region of the antibodies, expression vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies, cells comprising the vectors, and methods of making the antibodies or fragments by expressing them from the cells.
-
公开(公告)号:US20180298097A1
公开(公告)日:2018-10-18
申请号:US16017489
申请日:2018-06-25
Applicant: Bristol-Myers Squibb Company
Inventor: Xiao Min Schebye , Mark J. Selby , Michelle Minhua Han , Christine Bee , Andy X. Deng , Anan Chuntharapai , Brigitte Devaux , Huiming Li , Paul O. Sheppard , Alan J. Korman , Daniel F,. Ardourel , Ekaterina Deyanova , Richard Huang , Guodong Chen , Michelle Kuhne , Hong-An Troung
Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.
-
公开(公告)号:US10077306B2
公开(公告)日:2018-09-18
申请号:US15649380
申请日:2017-07-13
Applicant: Bristol-Myers Squibb Company
Inventor: Xiao Min Schebye , Mark J. Selby , Michelle Minhua Han , Christine Bee , Andy X. Deng , Anan Chuntharapai , Brigitte Devaux , Huiming Li , Paul O. Sheppard , Alan J. Korman , Daniel F. Ardourel , Ekaterina Deyanova , Richard Huang , Guodong Chen , Michelle Kuhne , Hong-An Troung
CPC classification number: C07K16/2803 , A61K47/6849 , A61K2039/505 , A61K2039/507 , A61P35/00 , C07K16/2818 , C07K16/2827 , C07K16/2878 , C07K16/30 , C07K16/3046 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/41 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/732 , C07K2317/734 , C07K2317/74 , C07K2317/76 , C07K2317/92 , C07K2317/94 , G01N33/57492
Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.
-
公开(公告)号:US20180037645A1
公开(公告)日:2018-02-08
申请号:US15694374
申请日:2017-09-01
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: Brenda L. Stevens , Alison Witte , Mark W. Rixon , Josephine M. Cardarelli , Thomas D. Kempe , Scott R. Presnell , Mohan Srinivasan , Susan C. Wong , Guodong Chen , Hui Wei , Stanley R. Krystek , Lumelle A. Schneeweis , Paul O. Sheppard , Indrani Chakraborty
CPC classification number: C07K16/244 , A61K2039/505 , C07K16/468 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
-
公开(公告)号:US20150086552A1
公开(公告)日:2015-03-26
申请号:US14402322
申请日:2013-05-21
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: Brenda L. Stevens , Alison Witte , Mark W. Rixon , Josephine M. Cardarelli , Thomas D. Kempe , Scott R. Presnell , Mohan Srinivasan , Susan C. Wong , Guodong Chen , Hui Wei , Stanley R. Krystek , Lumelle A. Schneeweis , Paul O. Sheppard , Indrani Chakraborty , Milan Gao , Steven Sheriff , Noah Ditto , Nels B. Hamacher
IPC: C07K16/24
CPC classification number: C07K16/244 , A61K2039/505 , C07K16/468 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
Abstract translation: 本发明涉及使用包含与IL-17A和IL-17F交叉反应的结合实体的双特异性抗体和结合IL-23p19的结合实体来拮抗IL-17A,IL-17F和IL-23的活性 。 本发明涉及新的双特异性抗体形式及其使用方法。
-
-
-
-
-
-
-
-
-